People news: Teva

Share this article:
Teva named former Bristol-Myers Squibb exec Dr. Jeremy Levin to replace Shlomo Yanai, who is retiring from his role as president and CEO of the generics giant in May. Levin joined BMS in 2007 as SVP strategy, alliances and transactions, also managing the company's portfolio of alliances. Before that he served as global head of business development and strategic alliances at Novartis. Yanai, said Teva, is “moving on to a new phase in his career” after five years in the president/CEO role. On his watch, the company went from an $8.4 billion mostly generics business in 2006 to a diversified Pharma with projected 2012 revenue of $22 billion.












Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.